Works matching IS 15391604 AND DT 2020 AND VI 19 AND IP 4
Results: 13
Counterpoint to Jin et al, On weighted composite scores for early Alzheimer's trials. Pharm Stat. 18 (2):239‐47, 2019, DOI: 10.1002/pst.1920.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 492, doi. 10.1002/pst.2007
- By:
- Publication type:
- Article
A resampling‐based test for two crossing survival curves.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 399, doi. 10.1002/pst.2000
- By:
- Publication type:
- Article
Designing cancer immunotherapy trials with delayed treatment effect using maximin efficiency robust statistics.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 424, doi. 10.1002/pst.2003
- By:
- Publication type:
- Article
START: single‐to‐double arm transition design for phase II clinical trials.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 454, doi. 10.1002/pst.2005
- By:
- Publication type:
- Article
Response to: Counterpoint to Jin et al, On weighted composite scores for early Alzheimer's trials. Pharm Stat. 18(2):239‐47, 2019, DOI: 10.1002/pst.1920.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 494, doi. 10.1002/pst.2008
- By:
- Publication type:
- Article
On evaluating how well a biomarker can predict treatment response with survival data.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 410, doi. 10.1002/pst.2002
- By:
- Publication type:
- Article
Estimation of group means using Bayesian generalized linear mixed models.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 482, doi. 10.1002/pst.2006
- By:
- Publication type:
- Article
Restricted mean survival time as a summary measure of time‐to‐event outcome.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 436, doi. 10.1002/pst.2004
- By:
- Publication type:
- Article
A novel quantification of information for longitudinal data analyzed by mixed‐effects modeling.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 388, doi. 10.1002/pst.1996
- By:
- Publication type:
- Article
Applications of Bayesian analysis to proof‐of‐concept trial planning and decision making.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 468, doi. 10.1002/pst.1985
- By:
- Publication type:
- Article
Study design of single‐arm phase II immunotherapy trials with long‐term survivors and random delayed treatment effect.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 358, doi. 10.1002/pst.1976
- By:
- Publication type:
- Article
What matters most? Different stakeholder perspectives on estimands for an invented case study in COPD.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 370, doi. 10.1002/pst.1986
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 4, p. 355, doi. 10.1002/pst.1960
- Publication type:
- Article